Treatment and outcomes of patients with relapsed, high‐risk neuroblastoma: Results of German trials (Q83381330)

From Wikidata

Jump to navigation Jump to search

scientific article published on 09 December 2010

edit

Language	Label	Description	Also known as
English	Treatment and outcomes of patients with relapsed, high‐risk neuroblastoma: Results of German trials	scientific article published on 09 December 2010

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21298742

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21298742%20AND%20SRC:MED&resulttype=core&format=json

retrieved

21 January 2020

title

Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21298742

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21298742%20AND%20SRC:MED&resulttype=core&format=json

retrieved

21 January 2020

Treatment and outcomes of patients with relapsed, high‐risk neuroblastoma: Results of German trials (English)

1 reference

stated in

Crossref

DOI

10.1002/PBC.22693

reference URL

https://api.crossref.org/works/10.1002/PBC.22693

retrieved

23 November 2024

main subject

neuroblastoma

1 reference

based on heuristic

inferred from title

author

Arndt Borkhardt

series ordinal

3

object named as

Arndt Borkhardt

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21298742

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21298742%20AND%20SRC:MED&resulttype=core&format=json

retrieved

21 January 2020

Thorsten Simon

series ordinal

1

object named as

Thorsten Simon

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21298742

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21298742

retrieved

23 November 2024

Frank Berthold

series ordinal

2

object named as

Frank Berthold

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21298742

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21298742

retrieved

23 November 2024

Boris Decarolis

series ordinal

5

object named as

Boris De Carolis

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21298742

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21298742

retrieved

23 November 2024

author name string

Bernhard Kremens

series ordinal

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21298742

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21298742%20AND%20SRC:MED&resulttype=core&format=json

retrieved

21 January 2020

Barbara Hero

series ordinal

6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21298742

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21298742%20AND%20SRC:MED&resulttype=core&format=json

retrieved

21 January 2020

language of work or name

English

1 reference

stated in

National Center for Biotechnology Information

PubMed publication ID

21298742

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21298742

retrieved

23 November 2024

publication date

9 December 2010

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21298742

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21298742%20AND%20SRC:MED&resulttype=core&format=json

retrieved

21 January 2020

full work available at URL

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fpbc.22693

1 reference

stated in

Crossref

DOI

10.1002/PBC.22693

reference URL

https://api.crossref.org/works/10.1002/PBC.22693

retrieved

23 November 2024

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.22693

1 reference

stated in

Crossref

DOI

10.1002/PBC.22693

reference URL

https://api.crossref.org/works/10.1002/PBC.22693

retrieved

23 November 2024

published in

Pediatric Blood & Cancer

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21298742

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21298742%20AND%20SRC:MED&resulttype=core&format=json

retrieved

21 January 2020

volume

56

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21298742

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21298742%20AND%20SRC:MED&resulttype=core&format=json

retrieved

21 January 2020

issue

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21298742

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21298742%20AND%20SRC:MED&resulttype=core&format=json

retrieved

21 January 2020

page(s)

578-583

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21298742

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21298742%20AND%20SRC:MED&resulttype=core&format=json

retrieved

21 January 2020

cites work

High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial

series ordinal

1

1 reference

stated in

Crossref

DOI

10.1002/PBC.22693

reference URL

https://api.crossref.org/works/10.1002/PBC.22693

retrieved

23 November 2024

Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial

series ordinal

2

1 reference

stated in

Crossref

DOI

10.1002/PBC.22693

reference URL

https://api.crossref.org/works/10.1002/PBC.22693

retrieved

23 November 2024

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group

series ordinal

3

1 reference

stated in

Crossref

DOI

10.1002/PBC.22693

reference URL

https://api.crossref.org/works/10.1002/PBC.22693

retrieved

23 November 2024

Long-term results and risk profiles of patients in five consecutive trials (1979-1997) with stage 4 neuroblastoma over 1 year of age.

series ordinal

5

1 reference

stated in

Crossref

DOI

10.1002/PBC.22693

reference URL

https://api.crossref.org/works/10.1002/PBC.22693

retrieved

23 November 2024

Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial

series ordinal

6

1 reference

stated in

Crossref

DOI

10.1002/PBC.22693

reference URL

https://api.crossref.org/works/10.1002/PBC.22693

retrieved

23 November 2024

Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma

series ordinal

7

1 reference

stated in

Crossref

DOI

10.1002/PBC.22693

reference URL

https://api.crossref.org/works/10.1002/PBC.22693

retrieved

23 November 2024

Intensified external-beam radiation therapy improves the outcome of stage 4 neuroblastoma in children > 1 year with residual local disease

series ordinal

8

1 reference

stated in

Crossref

DOI

10.1002/PBC.22693

reference URL

https://api.crossref.org/works/10.1002/PBC.22693

retrieved

23 November 2024

Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004.

series ordinal

9

1 reference

stated in

Crossref

DOI

10.1002/PBC.22693

reference URL

https://api.crossref.org/works/10.1002/PBC.22693

retrieved

23 November 2024

28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures

series ordinal

10

1 reference

stated in

Crossref

DOI

10.1002/PBC.22693

reference URL

https://api.crossref.org/works/10.1002/PBC.22693

retrieved

23 November 2024

Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution

series ordinal

11

1 reference

stated in

Crossref

DOI

10.1002/PBC.22693

reference URL

https://api.crossref.org/works/10.1002/PBC.22693

retrieved

23 November 2024

Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: results of a phase 2 trial

series ordinal

12

1 reference

stated in

Crossref

DOI

10.1002/PBC.22693

reference URL

https://api.crossref.org/works/10.1002/PBC.22693

retrieved

23 November 2024

Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group 'Survey' 1982-1992.

series ordinal

13

1 reference

stated in

Crossref

DOI

10.1002/PBC.22693

reference URL

https://api.crossref.org/works/10.1002/PBC.22693

retrieved

23 November 2024

Survival after relapse in children with solid tumors: a follow-up study from the Italian off-therapy registry

series ordinal

14

1 reference

stated in

Crossref

DOI

10.1002/PBC.22693

reference URL

https://api.crossref.org/works/10.1002/PBC.22693

retrieved

23 November 2024

A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors

series ordinal

15

1 reference

stated in

Crossref

DOI

10.1002/PBC.22693

reference URL

https://api.crossref.org/works/10.1002/PBC.22693

retrieved

23 November 2024

Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study

series ordinal

16

1 reference

stated in

Crossref

DOI

10.1002/PBC.22693

reference URL

https://api.crossref.org/works/10.1002/PBC.22693

retrieved

23 November 2024

A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study

series ordinal

17

1 reference

stated in

Crossref

DOI

10.1002/PBC.22693

reference URL

https://api.crossref.org/works/10.1002/PBC.22693

retrieved

23 November 2024

Topotecan in the treatment of refractory neuroblastoma and other malignant tumors in childhood - a phase-II-study

series ordinal

18

1 reference

stated in

Crossref

DOI

10.1002/PBC.22693

reference URL

https://api.crossref.org/works/10.1002/PBC.22693

retrieved

23 November 2024

Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study

series ordinal

19

1 reference

stated in

Crossref

DOI

10.1002/PBC.22693

reference URL

https://api.crossref.org/works/10.1002/PBC.22693

retrieved

23 November 2024

A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group study

series ordinal

20

1 reference

stated in

Crossref

DOI

10.1002/PBC.22693

reference URL

https://api.crossref.org/works/10.1002/PBC.22693

retrieved

23 November 2024

Phase I study of weekly oxaliplatin in relapsed or refractory pediatric solid malignancies

series ordinal

21

1 reference

stated in

Crossref

DOI

10.1002/PBC.22693

reference URL

https://api.crossref.org/works/10.1002/PBC.22693

retrieved

23 November 2024

Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study

series ordinal

22

1 reference

stated in

Crossref

DOI

10.1002/PBC.22693

reference URL

https://api.crossref.org/works/10.1002/PBC.22693

retrieved

23 November 2024

Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group Study

series ordinal

23

1 reference

stated in

Crossref

DOI

10.1002/PBC.22693

reference URL

https://api.crossref.org/works/10.1002/PBC.22693

retrieved

23 November 2024

Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study

series ordinal

24

1 reference

stated in

Crossref

DOI

10.1002/PBC.22693

reference URL

https://api.crossref.org/works/10.1002/PBC.22693

retrieved

23 November 2024

Severe enteropathy associated with raltitrexed and oxaliplatin chemotherapy: report of two patients experiencing this rare, potentially lethal gastrointestinal adverse event

series ordinal

25

1 reference

stated in

Crossref

DOI

10.1002/PBC.22693

reference URL

https://api.crossref.org/works/10.1002/PBC.22693

retrieved

23 November 2024

Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study

series ordinal

26

1 reference

stated in

Crossref

DOI

10.1002/PBC.22693

reference URL

https://api.crossref.org/works/10.1002/PBC.22693

retrieved

23 November 2024

Phase II study of temozolomide in relapsed or refractory high-risk neuroblastoma: a joint Société Française des Cancers de l'Enfant and United Kingdom Children Cancer Study Group-New Agents Group Study.

series ordinal

27

1 reference

stated in

Crossref

DOI

10.1002/PBC.22693

reference URL

https://api.crossref.org/works/10.1002/PBC.22693

retrieved

23 November 2024

A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: a European cooperation of the Société Française d'Oncologie Pédiatrique (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG).

series ordinal

28

1 reference

stated in

Crossref

DOI

10.1002/PBC.22693

reference URL

https://api.crossref.org/works/10.1002/PBC.22693

retrieved

23 November 2024

A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma.

series ordinal

29

1 reference

stated in

Crossref

DOI

10.1002/PBC.22693

reference URL

https://api.crossref.org/works/10.1002/PBC.22693

retrieved

23 November 2024

Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.

series ordinal

30

1 reference

stated in

Crossref

DOI

10.1002/PBC.22693

reference URL

https://api.crossref.org/works/10.1002/PBC.22693

retrieved

23 November 2024

Graft-versus-tumour effect in refractory metastatic neuroblastoma

series ordinal

31

1 reference

stated in

Crossref

DOI

10.1002/PBC.22693

reference URL

https://api.crossref.org/works/10.1002/PBC.22693

retrieved

23 November 2024

Evidence of graft-versus-tumor effect in refractory metastatic neuroblastoma

series ordinal

32

1 reference

stated in

Crossref

DOI

10.1002/PBC.22693

reference URL

https://api.crossref.org/works/10.1002/PBC.22693

retrieved

23 November 2024

Iodine-131-metaiodobenzylguanidine therapy with reduced-intensity allogeneic stem cell transplantation in recurrent neuroblastoma

series ordinal

33

1 reference

stated in

Crossref

DOI

10.1002/PBC.22693

reference URL

https://api.crossref.org/works/10.1002/PBC.22693

retrieved

23 November 2024

Antithymocyte globulin affects the occurrence of acute and chronic graft-versus-host disease after a reduced-intensity conditioning regimen by modulating mixed chimerism induction and immune reconstitution

series ordinal

34

1 reference

stated in

Crossref

DOI

10.1002/PBC.22693

reference URL

https://api.crossref.org/works/10.1002/PBC.22693

retrieved

23 November 2024

Graft-versus-tumor effect in a patient with advanced neuroblastoma who received HLA haplo-identical bone marrow transplantation

series ordinal

35

1 reference

stated in

Crossref

DOI

10.1002/PBC.22693

reference URL

https://api.crossref.org/works/10.1002/PBC.22693

retrieved

23 November 2024

Haploidentical stem cell transplantation in patients with pediatric solid tumors: preliminary results of a pilot study and analysis of graft versus tumor effects

series ordinal

36

1 reference

stated in

Crossref

DOI

10.1002/PBC.22693

reference URL

https://api.crossref.org/works/10.1002/PBC.22693

retrieved

23 November 2024

KIR-HLA receptor-ligand mismatch associated with a graft-versus-tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumors.

series ordinal

37

1 reference

stated in

Crossref

DOI

10.1002/PBC.22693

reference URL

https://api.crossref.org/works/10.1002/PBC.22693

retrieved

23 November 2024

Identifiers

DOI

10.1002/PBC.22693

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21298742

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21298742%20AND%20SRC:MED&resulttype=core&format=json

retrieved

21 January 2020

PubMed publication ID

21298742

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21298742

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21298742%20AND%20SRC:MED&resulttype=core&format=json

retrieved

21 January 2020

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q83381330&oldid=2279634775"